Oligoclonal B cell proliferation, as defined by the presence of more than one leukemic clone, has been detected in approximately 20% to 30% of patients with acute lymphoblastic leukemia (ALL) using PCR or Southern blotting. An accurate assessment of these populations is required to avoid false negative measurements of minimal residual disease (MRD) in follow-up bone marrow (BM) samples of ALL patients. In this study, we analysed 29 ALL patients with two or more immunoglobulin heavy (IGH) chain gene rearrangements in the presentation samples using IGH fingerprinting PCR and sequence analysis. Thirty-nine (51%) of 76 sequences (from 15 patients), shared no VNDNJ homology (ie different CDR3 regions). In the remaining 14 patients, at least two related VH sequences were identified in each patient (identical DNJ sequences). Numerical abnormalities of chromosome 14 was detected in 10 patients. Eight patients were analysed at presentation and relapse. In four of them, expansion of a minor presentation-clone was detected at relapse while the major presentation clone disappeared, confirming 'subclonal evolution'. Finally, in our cohort of patients, the presence of related or unrelated IGH clones did not influence overall survival. Leukemia (2001) 15, 1527-1536.
Introduction
Precursor B acute lymphoblastic leukemia (ALL) represents the clonal expansion of a B lineage committed lymphoid cell. Evidence of monoclonality was originally demonstrated by karyotype 1 and G6PD isotyping, 2 although immunological studies are routinely used to assess the clonal expansion of precursor B cells at varying stages of differentiation. The advent of molecular assessment, using immunoglobulin (IG) and T cell receptor (TCR) gene rearrangements 3 has revealed that what appeared on morphology and immunophenotype as an homogeneous population of precursor B cells, [4] [5] [6] may harbor up to four or five subclones in 20-30% of cases, as confirmed by Southern blotting [7] [8] [9] [10] and PCR analysis. [11] [12] [13] [14] [15] Oligoclonality per se appears to be restricted to B cell acute proliferations as it has been rarely described in acute myeloid leukemias. 16, 17 It occurs early in differentiation and it has only been reported in rare cases of B chronic lymphoid malignancies. [18] [19] [20] [21] [22] The identification of oligoclonality among ALL patients has become more relevant since Ig and TCR rearrangements have been used for monitoring minimal residual disease (MRD) in patients following chemotherapy or BMT. The incidence of false negative results due to oligoclonality has recently been reduced by accurate assessment of diagnostic samples 23 and by the use of multiple molecular targets. 24, 25 In the past, some studies have suggested an association between oligoclonality and both poor outcome 13 and higher WBC, 26 not confirmed in recent studies. Two principle mechanisms have been implicated in the occurrence of multiple IGH gene rearrangements in ALL: (1) the persistent activity of the recombinase machinery in the immature B cells in ALL; [28] [29] [30] and (2) duplication of chromosome 14 (involving the chromosome band 14q32, the locus harboring the IGH) 13 although the link between these two events has not been fully explored to date. The former results in VH replacement to VNDNJ pre-existing rearrangements 31, 32 or in an 'open-and-shut' VDJ modification as previously described in ALL patients. 15, [33] [34] [35] [36] V gene replacements can be distinguished into two main groups: (1) ongoing VH to DH-JH joining, when the part of a D segment and the D-J junction is shared by two or more rearrangements, but novel N nucleotides are inserted at the V-D junction; and (2) true VH replacements, with N-D-N-J junction preserved.
Although oligoclonality is detected more frequently in B, than in T cell proliferations, it clearly affects both IGH and TCR genes. 27, 37, 38 In this study, we have investigated the relationship between IGH VH gene rearrangements in leukemic cells from 29 ALL patients. The number of clonal IGH gene rearrangements was evaluated by the fingerprinting PCR method. The relationship between the different VH-JH gene rearrangements was assessed by sequence analysis of the rearranged gene and correlation with karyotype (particularly numerical abnormalities of chromosomes 14) and outcome was investigated.
Materials and methods

Patients characteristics and clinical follow-up
Twenty-nine patients (20 children and nine adults) from the Royal Free and University College London Hospital were investigated. Criteria for selection were as follows: (1) available VH gene rearrangement; (2) two or more IGH gene rearrangement; (3) availability of DNA from relapse stage (in the event of relapse). The purpose of this study was not to investigate the incidence of oligoclonality in ALL patients, but rather to investigate the biological and structural features associated with multiple VH-JH gene rearrangements. Eighteen were males and 11 females. Patients were diagnosed as ALL on the basis of morphology and immunophenotype as detailed in Table 1 . Fourteen patients had pre-B ALL, 15 had common ALL phenotype. All patients, except one child (B1) were tested as de novo cases. Five patients had a WBC over 50 × 10 9 /l (median 7.5 × 10 9 /l) ( Table 1) . Eleven patients suffered a clinical relapse, nine were medullary and two extramedullary (CNS) ( Table 1 ). The latter was confirmed to be associated with bone marrow relapse in one (A15), no material from the BM specimen in the second patient being available for analysis. First relapse occurred between 4.5 and 39.5 months from time of diagnosis (median relapse time 21 months). No changes in the immunophenotype were observed The patients have been divided into three groups. Group A, patients (Nos A1-A15) have two VH-JH gene rearrangements that are all unrelated by sequence analysis of the CDR3 region ( Figure 1a ). Group B, patients (Nos B1-B7) have sequences that are all related as their CDR3 sequences share extensive homology (Figure 1b ). Group C, patients (Nos C1-C7) have VH clones some of which show sequence homology and others that are unrelated to each other ( Figure 1c ). a Only chromosome 14 related abnormality was summarised. The number refers to the total number of chromosome 14 identified by cytogenetic analysis. In patient C3, duplication of only part of chromosome 14 was described. between presentation and relapse in eight patients studied at both time-points. Twenty patients have remained in complete clinical remission (CCR) to date between 8 and 74.5 months (median 22 months). Children received the UKALLX or UKALLXI protocols, and adults UKALLXII.
Cytogenetic analysis
Diagnostic bone marrow samples were prepared for cytogenetic analysis using standard techniques involving overnight culture and G-banding. Chromosomal abnormalities were identified and classified according to the International System for Human Cytogenetic Nomenclature.
Samples, PCR amplification cloning and sequencing of rearranged VH genes
Bone marrow specimens were used in the investigation of all patients both at presentation and relapse. Mononuclear cell, DNA extraction, qualitative assessment of each DNA sample prior to PCR amplification and PCR amplification of rearranged IGH genes was carried out as previously described. 39 All positive results were verified using a radiolabelled assay, previously reported. 40 VH clones were sequenced using an ABI 377 Sequencer (Warrington, UK), following cloning into plasmid Bluescript and sequences were then compared to published databases for the assignment of V, D and J segments (Figure 1a-c) . Table 1 and the CDR3 region presented as individual N, D and J segments. P nucleotides are the FR3 junction are presented in lower case characters. a, patients A1-A15; b, patients B1-B7; c, patients C1-C7. CDR3 region from AA 92 of the FR3 region only is reported. The presence of an in-frame (1) sequence or an out-of-frame (0) sequence is indicated at the JH junction. Out-of-frame sequences are separated in junctional out-of-frame (O/J) sequences or stop codon (0*) sequences. In-frame stop codons are highlighted by an asterix. The region of identity between two or more sequences in the same patient is underlined.
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Results
Chromosome 14 abnormalities
Cytogenetic analysis was successful in 25 patients, failed in two patients (B1 and C7) and was not available in two patients (A6 and B5). Only the occurrence of trisomy 14 or partial duplication involving 14q32 (the site of the IGH gene) are presented here. An additional copy of chromosome 14 was observed at presentation in nine patients, whilst duplication of 14q11-32 and unidentified chromosomal material on the long arm of chromosome 14 (add 14q) were observed in two children (Table 1 ). In 15 patients there was no cytogenetically detectable chromosome 14 numerical or structural abnormality.
Identification and analysis of IGH rearranged clones
Patients in this study were selected on the presence of two or more IGH gene rearrangements in the original referral sample. A total of 76 rearranged alleles was identified using fingerprinting and sequencing techniques (Figure 1a-c) . With the exception of one VH1 gene rearrangement (lack of sufficient material in patient A7) all rearranged VH genes were sequenced. On the basis of sequence analysis of rearranged VH genes, patients could be classified into three subgroups (A, B and C). Data from each group are presented and analysed separately.
Group A: patients with unrelated rearranged IGH genes:
Fifteen patients (Nos A1-A15) showed two (13 patients) or more (A5 and A7) rearranged IGH alleles. A total of 33 IGH rearrangements were identified of which 32 were sequenced ( Figure 1a) . None of the rearrangements showed any sequence homology across the CDR3 region, both at the VND and DNJ junction. Trisomy 14 was observed in six of the 14 patients analysed in this group. Only one patient with trisomy 14 showed more than two IGH rearranged sequences (A7). Three IGH rearrangements were present in two patients without trisomy 14 (A5 and A15).
Group B: patients with two related IGH rearrangements:
In seven patients (B1-B7), 19 IGH gene rearrangements were analysed. All VH rearranged sequences showed homology at the DNJ junction (Figure 1b) . Two of five patients had trisomy 14 and in one, five IGH rearrangements were identified. One patient (B7) had add(14q) observed only at relapse. This case is described in detail below. Four rearrangements were described in a patient without trisomy 14 (B3).
Group C: patients with related and unrelated IGH gene rearrangements:
In seven patients (C1-C7), three or more rearrangements were detected. Sequence analysis showed a mixture of related (18 of 25 identical DNJ) and unrelated (different DNJ) sequences (Figure 1c ). This group showed the most complex rearrangements. Between three and seven (in patient C1) VH sequences were identified. Only three of six patients analysed, showed trisomy 14. Multiple IGH clones existed in four patients without trisomy 14.
Leukemia
IGH rearrangement and phenotype
The open reading frames (ORF) of each IGH rearrangement was investigated across the CDR3 junctional region. Five (33%) of 15 cALL and 12 (85.7%) of 14 pre-B-ALL showed at least one in-frame sequence (17, 58.6%, of 29 patients). In two pre-B-ALL patients no in-frame sequences were detected (A13 and C4).
Heavy chain V gene replacement in ALL
The persistent activity of the recombinase machinery in B cells is most often considered responsible for IGH gene replacement involving VH segments leading to oligoclonality in ALL, as discussed above. To investigate this model, we matched the rearranged IGH genes to their germline counterparts in 13 patients (from group B and C of this study), who carried related sequences (identical DNJ, but different VND) and analysed the molecular features of the CDR3 region (the number of DH elements and size of N regions). These features are believed to correlate directly with the stage of B cell maturation, as recently described. 41 From the distance of VH genes from the JH segments, 42, 43 and features of the rearranged VH genes, we establish the physical and temporal sequences of the different VH gene rearrangements. This analysis showed that a distal VH gene in each case (Table 2) had replaced a proximal (to the JH segments) VH gene. The distance of rearranged VH genes varied between 70 and 855 kb (median 395 kb) (from the JH segments) and genes from different parts of the VH locus were used. The distance between two VH genes involved in related rearrangements varied between 10 kb and 410 kb (median distance 150 kb). The rearrangements involving the more distal VH gene were associated with a longer N region at the VND junction. For example, in case B1, the VH3 rearrangement involved V3-33 at approximately 495 kb (from the JH region) while the VH4 rearrangement involved V4-34, at 505 kb, 10 kb telomeric to V3-33. The VND junction in the latter was also 10 bp longer. V4-34 replaced V3-33 and during the process additional TdT-associated activity induced further addition of N regions. This pattern was seen in another nine patients, but it was not the sole model observed. In patient C4, V2-5 was replaced by V3-13. This rearrangement was associated with trimming of the DH 1-7 element prior to the generation of a new VND junction. Although the VNDN region appears to be shorter, the extra trimming of the DH elements indicates a later rather than an earlier joining, as the size of the N region would initially suggest. Also, case C1 illustrates that VND junction size comparison is not the only consideration, as this alone would lead to a wrong conclusion on the order of VH replacements. It is logical to assume that this process involves segments distal to the one being replaced. In patient C1, the order of VH usage must have been: VH6 followed by VH5 and finally VH3.
Finally, this analysis identified a rare type of IGH rearrangement, similar to a previously described case reported by Li and colleagues. 44 In patient B7, both a major (VH3) and a minor (VH4) rearranged clone was identified by fingerprinting PCR 39 at presentation. The rearrangements involved the V3-22, a VH3 pseudogene at 385 kb from the JH region (major clone) and the V4-55 (minor clone), also a pseudogene located at 735 kb from the JH region. The latter rearrangement clearly followed the VH3 rearrangement. This was ascertained from the observation that both genes were in the same transcriptional orientation as the JH segments and that rearrange- (Figure 2 and text) . The process is associated with the insertion of N nucleotides at the junctional region. e Median value of four different VH6 sequences. R, relapse; Ps, pseudogene; NA, not available as the patient was referred to our institution at time of first relapse.
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ment of VH4 would involve the deletion of VH3. The VH4 rearrangement at replase shows sequences from the VH3 gene in the FR3 region ( Figure 2 ) and the VH4 replacement occurred across the 3Ј part of the VH3 gene. In the process 23 bp long N region was added. In addition, it was observed that the VH4 clone, dominant at the time of relapse, was clearly identified at presentation by fingerprinting and ASO analysis ( Figure 3 , patient B7). The VH3 rearrangement, a major clone at presentation, was not detectable at relapse. In a recent investigation 45 the VH4 clone, but not the VH3 clone, was found to carry a p53 mutation, which may have provided a growth advantage and resistance to treatment.
VH gene rearrangement: relapse rate
The overall clinical outcome in patients with related VH sequences was compared to patients carrying unrelated sequences (Figure 4 ). Overall survival rate was not better in the former than in the latter group. We observed no differences in sex, age and immunophenotype among the three subgroups. Only WBC total median count was higher (15.7 × 10 9 /l) in group A than in the other two groups (4.7 and 10.2 × 10 9 /l, respectively).
VH gene rearrangement: comparison between presentation and relapse
Material from presentation and relapse was analysed in eight of 11 relapsed cases with available (A4, A7, A10, A11, A15, B4, B7 and C6). Pattern of gene rearrangement of patients A7, A10 and B7 is illustrated in Figure 3 . ASO derived from presentation material were used on relapse DNA, and vice versa. In four patients (A4, A7, A10 and C6) the major clone remained unchanged in pattern and sequence. In the remaining four cases (A11, A15, B4 and B7), we observed an inversion in the relative intensity of VH gene patterns. The major clone at presentation disappeared (B4 and B7) or was reduced in intensity (A11 and A15) and the minor clone (at presentation) became the major clone at relapse (Figure 3 , case B7). Variation in the intensity of minor clones was also observed in several patients (Figure 3, patient A7) . As previously described, 44 despite ongoing IGH events, at least one VH rearrangement remained unchanged throughout the course of the disease. Compared to Southern blotting, fingerprinting (particularly when the PCR product is radiolabelled and separated on to a denaturing gel) provides a more sensitive method for the monitoring of different clones during the progression of disease, in individual patients (Figure 3) . IGH gene rearrangement pattern differences between presentation (P) and relapse (R). Patients are listed as from Table 1 . The fingerprinting pattern (top part) and the pattern obtained using three individual allele-specific primers (bottom) are illustrated. In patient B7, the presentation VH3 clone disappeared and was replaced by the VH4 clone (see text for additional description of this case). In patients A7, we observed a mixture of clonal variation: the major VH2 clone persisted, but the VH3 disappeared and the VH5 became much more prominent. In patient A10, the minor clone disappeared while no change was observed in the intensity of the VH3 clone.
VH family usage
VH gene usage was analysed and compared to the germline and rearranged VH genes described in recent studies. 42, 43 The predominance of VH3 (37%) and VH4 (21%) usage was confirmed in the group as a whole or in the different subgroups. There was an increase (12%) in the number of rearrangements involving VH6, particularly in group C, in agreement with our Leukemia previous and recent observations, 40, 46 while VH1 and VH5 were within the expected range 46 (13% and 5%, respectively).
Discussion
Oligoclonality, which is almost exclusively restricted to immature B cell precursor ALL, is clearly a biologically important
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Figure 4
Overall disease survival for patients with related (open circle) and unrelated (close circles) VH rearrangements. phenomenon in ALL. Previous studies have shown that 20 to 30% of ALL show evidence of oligoclonality, irrespective of the approach used (Southern blotting or PCR). These studies have suggested that multiple IGH gene rearrangements are due to at least two possible mechanisms, involving (1) VH replacement to pre-existing V-D-JH rearrangements; and (2) open-and-shut VH events in a B cell with a still active VDJ recombinase machinery resulting in biologically related clones. Our study reveals that 49% of VH rearranged clones among patients carrying at least two rearranged IGH genes were the results of ongoing VH rearrangements. Unrelated clones (different CDR3 sequences) were present in 51% of cases. The presence of unrelated rearrangements is the results of (1) biallelic rearrangement (in one monoclonal B cell population; C pattern in Figure 5 ); or (2) the independent proliferation of cells hit by the leukemic transformation at different stages of differentiation (pattern A1-A2 in Figure 5 ). In pattern C, the intensity of the rearrangements would be identical irrespective of the method used. A trisomy 14 or duplication of 14q would have the same result. In pattern A1 and A2, the two B cell populations can be comparable in size or more commonly of different sizes, giving rise to signals of differing intensities on Southern blotting and this pattern could be referred to as 'true oligoclonality'. One of the two clones could even escape Southern blotting detection, but not PCR. Although this event is rare, it is not impossible. The presence of two independent clones in patients with paroxysmal nocturnal hemoglobinuria (PNH) has for instance been previously described. 47 Patients in group A of our study (Figure 1a ) could be examples of this pattern.
In at least half of the patients IGH genes show features of 'on-going' VH rearrangements (pattern B in Figure 5 ). During clonal expansion, as a result of discrete molecular events, two or more subclones are generated from one leukemic clone. Consequently, one subclone emerges from a cell, which already carries a rearrangement generating what appears (by PCR and Southern blotting) to be an independent rearrangement. The two rearrangements appear of different intensities because of differences in the relative amount/ratio of the clones to one another, and this could be referred to as 'subclonal evolution' or 'oligo-subclonality'. Patients in group B are examples of this pattern. Finally, a combination of pattern A and B could also exist as probably some patients in our group C. To discriminate between the above situations singlecell PCR and FISH could be applied, as previously described, 37 but it is not a feasible approach for routine diagnostic analyses. In their study, Ghali and colleagues 37 elegantly showed that each rearrangement occurred independently in a separate B cell and that the clonal population was the true mixture of two independent B cell clones. Other investigators 34 postulated that oligoclonal B cell proliferations represent the malignant counterpart of normal B cell proliferation in which 'ongoing VH rearrangements' are a method of achieving functional IGH chain production in B cell during maturation, but this remains to be fully evaluated in humans.
Finally, in our study, we showed that over 60% of VH rearrangements in ALL result in an in-frame CDR3 region, in agreement with previous reports, 36, 41 but not others. 48 The authors of the latter study, found only a minority of ALL patients with productive rearrangements and postulated that this pattern was an ALL-specific/associated feature and suggested that cells carrying unproductive rearrangements were more likely to give rise to leukemic clones than productive rearrangements.
The IGH allele could undergo rearrangement and then duplicate as a result of trisomy 14 in ALL. There is no reason to believe that the duplicated allele could not undergo further IGH rearrangements independently and consequently contribute to oligoclonality. More extensive investigation is required to clarify the link between trisomy 14 and oligoclonality.
Changes in clonality between presentation and relapse has been described previously in 40-50% of both monoclonal and oligoclonal cases. This initial high incidence detected by Southern blotting 11 has not been confirmed by accurate molecular monitoring which shows an incidence of only 5-8% 49 or lower. 23 The discrepancies may be due to the differences in sensitivity of the two procedures. Novel PCR strategies have been devised to avoid false negative results in oligoclonal cases. These include the use of DNJ and not VND primers 35, 49 and the use of multiple molecular targets (TCRD, TCRG and lG light chains). 25 These issues are highly relevant to the investigation of MRD in ALL. However, the latter are secondary to IGH rearrangement in B precursor ALL 27, 37, 50, 51 and therefore less reliable as clonal markers for long-term followup analysis and may give rise to false negative results.
Finally, our study showed that relapse is associated with changes in the size of different VH-JH gene rearrangements, rather than the emergence of totally new IGH clones. We detected this pattern in four of eight relapsed patients. Accurate assessment of presentation and relapse material must be introduced into MRD large scale studies. IGH fingerprinting remains, in our experience a most reliable approach to achieving such an aim.
Our study has found little evidence to support the previously described association between oligoclonality, trisomy 14 and higher relapse rate. 13 However, we observed higher relapse incidence among patients with independent/unrelated IGH clones than patients with related sequences (57% vs 22%, respectively). We postulate that related clones are likely to be both molecularly (similar DNJ sequence) and biologically related and they may represent a more homogenous target for treatment. Our study has established the clinical importance of identifying such cases albeit in a small series of Leukemic clonal expansion. Pattern A depicts the emergence from a leukemic hit of one (A1) or two independent leukemic cell populations (A1 and A2). This is likely to be a rare event but may represent a 'true oligoclonal proliferation'. A biallelic rearrangement could also appear as distinct IGH rearrangements (C pattern) within a monoclonal expansion. Pattern B depicts the pattern observed in patients of group B in this study. From one monoclonal B cell population, 'subclonal evolution' is observed by comparing IGH sequences that share extensive nucleotide homology. Patients in our study from group C appear to have a mixed pattern of expansion A and B.
patients and additional analysis should be extended to a larger cohort of patients.
